{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:18:54Z","timestamp":1786119534395,"version":"build-2736575974"},"reference-count":113,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Anaemia, a condition characterized by low levels of haemoglobin, is frequently observed in patients with heart failure (HF). Guideline-directed medical therapy improves HF outcomes by using medications like beta blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers, along with mineralocorticoid receptor antagonists and sodium-glucose cotransporter 2 inhibitors. In this study, we aimed to review the pathophysiology of anaemia in patients with HF and present the current evidence regarding the relationship between the main recommended medications for these patients and haemoglobin levels. The authors conducted a comprehensive search in the medical literature for relevant original clinical articles in which the four pharmacological pillars of HF were given to the patients; we, then, assessed whether the association of use of these medications and haemoglobin level or development of anaemia was provided. These common medications have been shown in the literature that may exacerbate or ameliorate anaemia. Besides, it has been shown that even in the case that they result in the development of anaemia, their use is associated with positive effects that outweigh this potential harm. The literature also suggests that among patients receiving medications with negative effects on the level of haemoglobin, there was no difference in the rate of mortality between anaemic and non-anaemic patients when both were on treatment for anaemia; this point highlights the importance of the detection and treatment of anaemia in these patients. Further research is needed to explore these relationships and identify additional strategies to mitigate the risk of anaemia in this population.<\/jats:p>","DOI":"10.1097\/ms9.0000000000001773","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T01:00:09Z","timestamp":1706230809000},"page":"1575-1583","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["The effect of the four pharmacological pillars of heart failure on haemoglobin level"],"prefix":"10.1097","volume":"86","author":[{"given":"Darshan","family":"Hullon","sequence":"first","affiliation":[{"name":"MercyOne Clinton Medical Center, Clinton, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Taherifard","sequence":"additional","affiliation":[{"name":"Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taif Haitham","family":"Al-Saraireh","sequence":"additional","affiliation":[{"name":"Prince Hamzah Hospital, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,3]]},"reference":[{"key":"R1-20250806","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.jacc.2008.04.061","article-title":"Anemia and mortality in heart failure patients a systematic review and meta-analysis","volume":"52","author":"Groenveld","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250806","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/CIRCULATIONAHA.105.583666","article-title":"Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options","volume":"113","author":"Tang","year":"2006","journal-title":"Circulation"},{"key":"R3-20250806","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11739-020-02343-x","article-title":"Association between anemia and outcome in patients hospitalized for acute heart failure syndromes: findings from Beijing Acute Heart Failure Registry (Beijing AHF Registry)","volume":"16","author":"Ye","year":"2021","journal-title":"Intern Emergy Med"},{"key":"R4-20250806","first-page":"237","article-title":"Managing anemia in patients with chronic heart failure: what do we know?","volume":"6","author":"Sandhu","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"R5-20250806","doi-asserted-by":"crossref","first-page":"632318","DOI":"10.3389\/fcvm.2021.632318","article-title":"The prognostic significance of anemia in patients with heart failure: a meta-analysis of studies from the last decade. systematic review","volume":"8","author":"Xia","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R6-20250806","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2012.05.036","article-title":"Health-related quality of life and anemia in hospitalized patients with heart failure","volume":"161","author":"Kraai","year":"2012","journal-title":"Int J Cardiol"},{"key":"R7-20250806","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10389-018-0915-7","article-title":"Health-related quality of life in outpatients with chronic heart failure associated with sideropenic anemia","volume":"26","author":"Djukic","year":"2018","journal-title":"J Public Health"},{"key":"R8-20250806","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ahj.2009.10.015","article-title":"Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure","volume":"158","author":"Adams","year":"2009","journal-title":"Am Heart J"},{"key":"R9-20250806","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cardfail.2009.06.435","article-title":"Relationship between anemia and health care costs in heart failure","volume":"15","author":"Allen","year":"2009","journal-title":"Journal of Cardiac Failure"},{"key":"R10-20250806","first-page":"52","article-title":"Anemia in heart failure\u2014from guidelines to controversies and challenges","volume":"20","author":"S\u00eerbu","year":"2018","journal-title":"Anatol J Cardiol"},{"key":"R11-20250806","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jchf.2017.08.023","article-title":"Anemia in heart failure","volume":"6","author":"Grote Beverborg","year":"2018","journal-title":"Still Relevant? JACC Heart Fail"},{"key":"R12-20250806","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.jacc.2006.08.034","article-title":"Etiology of anemia in patients with advanced heart failure","volume":"48","author":"Nanas","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R13-20250806","first-page":"111","article-title":"Anemia associated with chronic heart failure: current concepts","volume":"8","author":"Shah","year":"2013","journal-title":"Clin Interv Aging"},{"key":"R14-20250806","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.0000134279.79571.73","article-title":"Anemia and its relationship to clinical outcome in heart failure","volume":"110","author":"Anand","year":"2004","journal-title":"Circulation"},{"key":"R15-20250806","article-title":"Anemia and heart failure: guidance for clinicians and trialists. Expert Analysis","author":"Silver","year":"2021","journal-title":"Am College Cardiol"},{"key":"R16-20250806","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"R17-20250806","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.hfc.2020.12.002","article-title":"Anemia and management of heart failure patients","volume":"17","author":"Beladan","year":"2021","journal-title":"Heart Fail Clin"},{"key":"R18-20250806","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3390\/medicina55070329","article-title":"The influence of cardiovascular medications on iron metabolism in patients with heart failure","volume":"55","author":"Sirbu","year":"2019","journal-title":"Medicina (Kaunas)"},{"key":"R19-20250806","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1524-6175.2007.06296.x","article-title":"Antihypertensive medications and anemia","volume":"9","author":"Sica","year":"2007","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"R20-20250806","doi-asserted-by":"crossref","first-page":"709872","DOI":"10.3389\/fcvm.2021.709872","article-title":"Iron deficiency: a new target for patients with heart failure","volume":"8","author":"Rizzo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"R21-20250806","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamacardio.2019.1739","article-title":"Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies","volume":"4","author":"Grote Beverborg","year":"2019","journal-title":"JAMA Cardiol"},{"key":"R22-20250806","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/00005082-200603000-00008","article-title":"Factors influencing food intake in patients with heart failure: a comparison with healthy elders","volume":"21","author":"Lennie","year":"2006","journal-title":"J Cardiovasc Nurs"},{"key":"R23-20250806","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jacc.2014.06.1179","article-title":"Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia","volume":"64","author":"Sandek","year":"2014","journal-title":"J Am College Cardiol"},{"key":"R24-20250806","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacc.2007.07.016","article-title":"Article title Altered intestinal function in patients with chronic heart failure","volume":"50","author":"Sandek","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"key":"R25-20250806","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1093\/eurheartj\/ehz680","article-title":"Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use","volume":"40","author":"van der Wal","year":"2019","journal-title":"J Eur Heart J"},{"key":"R26-20250806","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.030099","article-title":"Anemia and Iron Deficiency in Heart Failure","volume":"138","author":"Anand","year":"2018","journal-title":"Circulation"},{"key":"R27-20250806","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000243791","article-title":"The role of hepcidin in iron metabolism","volume":"122","author":"Nemeth","year":"2009","journal-title":"Acta Haematol"},{"key":"R28-20250806","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.3390\/ijms23105341","article-title":"Iron Mining for Erythropoiesis","volume":"23","author":"Correnti","year":"2022","journal-title":"International Journal of Molecular Sciences"},{"key":"R29-20250806","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1182\/blood-2011-01-330241","article-title":"Hepcidin regulates ferroportin expression and intracellular iron homeostasis of erythroblasts","volume":"118","author":"Zhang","year":"2011","journal-title":"Blood"},{"key":"R30-20250806","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1182\/blood-2005-07-2854","article-title":"Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations","volume":"107","author":"Dallalio","year":"2006","journal-title":"Blood"},{"key":"R31-20250806","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s11897-017-0337-9","article-title":"Inflammation\u2014cause or consequence of heart failure or both?","volume":"14","author":"Van Linthout","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"R32-20250806","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/01.CIR.93.4.704","article-title":"Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart","volume":"93","author":"Torre-Amione","year":"1996","journal-title":"Circulation"},{"key":"R33-20250806","doi-asserted-by":"crossref","first-page":"246915","DOI":"10.5402\/2012\/246915","article-title":"Anemia in heart failure patients","volume":"2012","author":"Alexandrakis","year":"2012","journal-title":"ISRN Hematol"},{"key":"R34-20250806","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10741-010-9168-4","article-title":"Proinflammatory cytokines in heart failure: double-edged swords","volume":"15","author":"Hedayat","year":"2010","journal-title":"Heart Fail Rev"},{"key":"R35-20250806","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/ejhf.1482","article-title":"The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study","volume":"21","author":"Markousis-Mavrogenis","year":"2019","journal-title":"Eu J Heart Fail"},{"key":"R36-20250806","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000338166","article-title":"Inflammatory cytokines in heart failure: mediators and markers","volume":"122","author":"Gullestad","year":"2012","journal-title":"Cardiology"},{"key":"R37-20250806","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","article-title":"Interleukin-6 induces hepcidin expression through STAT3","volume":"108","author":"Wrighting","year":"2006","journal-title":"Blood"},{"key":"R38-20250806","doi-asserted-by":"crossref","first-page":"405016","DOI":"10.1155\/2009\/405016","article-title":"Pro-inflammatory cytokine-mediated anemia: regarding molecular mechanisms of erythropoiesis","volume":"2009","author":"Morceau","year":"2009","journal-title":"Mediators Inflamm"},{"key":"R39-20250806","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ncpneph0655","article-title":"Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure","volume":"4","author":"van der Putten","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"R40-20250806","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"key":"R41-20250806","first-page":"108","article-title":"Renin-angiotensin-aldosterone system activation during decongestion in acute heart failure: friend or foe?\u2217","volume":"3","author":"Verbrugge","year":"2015","journal-title":"JACC: Heart Faile"},{"issue":"Suppl 5","key":"R42-20250806","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198600325-00002","article-title":"Endocrine mechanisms in congestive cardiac failure. Renin, aldosterone and atrial natriuretic hormone","volume":"32","author":"Laragh","year":"1986","journal-title":"Drugs"},{"key":"R43-20250806","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/eurheartj\/ehl419","article-title":"Anaemia in chronic heart failure is not only related to impaired renal perfusion and blunted erythropoietin production, but to fluid retention as well","volume":"28","author":"Westenbrink","year":"2007","journal-title":"Eur Heart J"},{"key":"R44-20250806","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/01.CIR.0000052623.16194.80","article-title":"Hemodilution is common in patients with advanced heart failure","volume":"107","author":"Androne","year":"2003","journal-title":"Circulation"},{"key":"R45-20250806","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1136\/heartjnl-2014-306022","article-title":"Vitamin B12 and folate deficiency in chronic heart failure","volume":"101","author":"van der Wal","year":"2015","journal-title":"Heart"},{"key":"R46-20250806","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Journal of the American College of Cardiology"},{"key":"R47-20250806","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1136\/heartjnl-2021-319229","article-title":"Heart failure medication dosage and survival in women and men seen at outpatient clinics","volume":"107","author":"Bots","year":"2021","journal-title":"Heart"},{"key":"R48-20250806","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","article-title":"Heart failure drug treatment: the fantastic four","volume":"42","author":"Bauersachs","year":"2021","journal-title":"Eur Heart J"},{"key":"R49-20250806","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/jamacardio.2020.0898","article-title":"Association of optimal implementation of sodium-glucose cotransporter 2 inhibitor therapy with outcome for patients with heart failure","volume":"5","author":"Bassi","year":"2020","journal-title":"JAMA Cardiol"},{"key":"R50-20250806","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1093\/eurheartj\/ehl012","article-title":"The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET","volume":"27","author":"Komajda","year":"2006","journal-title":"Eur Heart J"},{"key":"R51-20250806","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"R52-20250806","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(03)13801-9","article-title":"Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial","volume":"362","author":"Cleland","year":"2003","journal-title":"Lancet"},{"key":"R53-20250806","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijcard.2016.10.046","article-title":"Protective effects of bisoprolol against myocardial injury and pulmonary dysfunction in patients with chronic heart failure","volume":"226","author":"Toyoda","year":"2017","journal-title":"Int J Cardiol"},{"key":"R54-20250806","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.ijcard.2013.01.277","article-title":"Multiparametric comparison of CARvedilol, vs. NEbivolol, vs. BIsoprolol in moderate heart failure: the CARNEBI trial","volume":"168","author":"Contini","year":"2013","journal-title":"Int J Cardiol"},{"key":"R55-20250806","doi-asserted-by":"crossref","first-page":"e26892","DOI":"10.1097\/MD.0000000000026892","article-title":"Improved and new-onset anemia during follow-up in patients with acute decompensated heart failure: Characteristics and outcomes","volume":"100","author":"Seko","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"R56-20250806","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.rec.2016.02.028","article-title":"Hemoglobin Kinetics and Long-term Prognosis in Heart Failure","volume":"69","author":"D\u00edez-L\u00f3pez","year":"2016","journal-title":"Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition)"},{"key":"R57-20250806","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1136\/hrt.2005.083998","article-title":"Beta blocker treatment is associated with improvement in renal function and anaemia in patients with heart failure","volume":"92","author":"Khan","year":"2006","journal-title":"Heart"},{"key":"R58-20250806","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1253\/circj.CJ-17-0442","article-title":"Anemia is associated with blunted response to \u03b2-blocker therapy using carvedilol-insights from japanese chronic heart failure (J-CHF) Study","volume":"82","author":"Nagatomo","year":"2018","journal-title":"Circ J"},{"key":"R59-20250806","doi-asserted-by":"crossref","first-page":"e90240","DOI":"10.1172\/jci.insight.90240","article-title":"Hypoxia sensing through \u03b2-adrenergic receptors","volume":"1","author":"Cheong","year":"2016","journal-title":"JCI Insight"},{"key":"R60-20250806","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.1984.tb03959.x","article-title":"Adrenergic modulation of erythropoiesis: in vitro studies of colony-forming cells in normal and polycythaemic man","volume":"56","author":"Mladenovic","year":"1984","journal-title":"Br J Haematol"},{"key":"R61-20250806","doi-asserted-by":"crossref","first-page":"F113","DOI":"10.1152\/ajprenal.00478.2010","article-title":"Chronic vasodilation produces plasma volume expansion and hemodilution in rats: consequences of decreased effective arterial blood volume","volume":"300","author":"Fekete","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"R62-20250806","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1161\/01.CIR.92.2.212","article-title":"Effects of carvedilol, a vasodilator\u2013\u03b2-blocker, in patients with congestive heart failure due to ischemic heart disease","volume":"92","year":"1995","journal-title":"Circulation"},{"key":"R63-20250806","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/HJH.0b013e3280127948","article-title":"Antioxidant activity of carvedilol in cardiovascular disease","volume":"25","author":"Dandona","year":"2007","journal-title":"J Hypertens"},{"key":"R64-20250806","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1161\/01.CIR.0000018605.14470.DD","article-title":"Carvedilol decreases elevated oxidative stress in human failing myocardium","volume":"105","author":"Nakamura","year":"2002","journal-title":"Circulation"},{"key":"R65-20250806","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0735-1097(00)01121-9","article-title":"Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy","volume":"37","author":"Ohtsuka","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R66-20250806","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jjcc.2019.07.011","article-title":"Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure","volume":"75","author":"Toyoda","year":"2020","journal-title":"J Cardiol"},{"key":"R67-20250806","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/qjmed\/hcv049","article-title":"Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis","volume":"108","author":"Cheungpasitporn","year":"2015","journal-title":"QJM Int J Med"},{"key":"R68-20250806","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jacc.2004.10.038","article-title":"Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction","volume":"45","author":"Ishani","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R69-20250806","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1161\/CIRCULATIONAHA.104.512988","article-title":"Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT","volume":"112","author":"Anand","year":"2005","journal-title":"Circulation"},{"key":"R70-20250806","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MAJ.0b013e318095a4ae","article-title":"The role of the kidney in blood volume regulation: the kidney as a regulator of the hematocrit","volume":"334","author":"Dunn","year":"2007","journal-title":"Am J Med Sci"},{"key":"R71-20250806","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/bs.vh.2017.02.001","article-title":"Erythropoietin regulation by angiotensin II","volume":"105","author":"Kim","year":"2017","journal-title":"Vitam Horm"},{"key":"R72-20250806","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1172\/JCI119769","article-title":"Angiotensin II stimulates proliferation of normal early erythroid progenitors","volume":"100","author":"Mrug","year":"1997","journal-title":"J Clin Invest"},{"key":"R73-20250806","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00394-014-0749-1","article-title":"Angiotensin II alters the expression of duodenal iron transporters, hepatic hepcidin, and body iron distribution in mice","volume":"54","author":"Tajima","year":"2015","journal-title":"Eur J Nutr"},{"key":"R74-20250806","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/00007890-199709270-00021","article-title":"Interference of angiotensin-converting enzyme inhibitors on erythropoiesis in kidney transplant recipients: role of growth factors and cytokines","volume":"64","author":"Morrone","year":"1997","journal-title":"Transplantation"},{"key":"R75-20250806","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-2478(98)00025-X","article-title":"Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells","volume":"62","author":"Constantinescu","year":"1998","journal-title":"Immunol Lett"},{"key":"R76-20250806","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1161\/CIRCULATIONAHA.105.549121","article-title":"Levels of hematopoiesis inhibitor N-acetyl-seryl-aspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure","volume":"112","author":"van der Meer","year":"2005","journal-title":"Circulation"},{"key":"R77-20250806","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/ndt\/14.8.1836","article-title":"The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin","volume":"14","author":"Macdougall","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"R78-20250806","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41440-021-00706-1","article-title":"Angiotensin receptor-neprilysin inhibitors: comprehensive review and implications in hypertension treatment","volume":"44","author":"Yamamoto","year":"2021","journal-title":"Hypertens Res"},{"key":"R79-20250806","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cardiores.2005.10.001","article-title":"The role of natriuretic peptides in cardioprotection","volume":"69","author":"Nishikimi","year":"2006","journal-title":"Cardiovasc Res"},{"key":"R80-20250806","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2004.04.004","article-title":"Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance","volume":"102","author":"Abassi","year":"2004","journal-title":"Pharmacol Ther"},{"key":"R81-20250806","doi-asserted-by":"crossref","first-page":"14415","DOI":"10.3390\/ijms232214415","article-title":"Role of cardiac natriuretic peptides in heart structure and function","volume":"23","author":"Sarzani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R82-20250806","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacbts.2022.05.010","article-title":"Neprilysin inhibitors in heart failure: the science, mechanism of action, clinical studies, and unanswered questions","volume":"8","author":"Bozkurt","year":"2022","journal-title":"JACC Basic to Translation Sci"},{"key":"R84-20250806","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"R86-20250806","doi-asserted-by":"crossref","first-page":"8186","DOI":"10.1038\/s41598-022-11886-2","article-title":"Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril\u2013valsartan","volume":"12","author":"Yang","year":"2022","journal-title":"Sci Rep"},{"key":"R87-20250806","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/1871525718666200506095537","article-title":"Sacubitril-Valsartan improves anemia of cardiorenal syndrome (CRS)","volume":"19","author":"Robles","year":"2021","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"R88-20250806","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"R89-20250806","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2010","journal-title":"The New England Journal of Medicine"},{"key":"R90-20250806","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1253\/circj.CJ-17-0323","article-title":"Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese Patients with Chronic Heart Failure (J-EMPHASIS-HF)","volume":"82","author":"Tsutsui","year":"2017","journal-title":"Circ J"},{"key":"R91-20250806","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"R92-20250806","doi-asserted-by":"crossref","first-page":"350","DOI":"10.5414\/CN107677","article-title":"Aldosterone blockade as an alternative renin-angiotensin-aldosterone system blocking agent in cases of treatment associated anemia","volume":"81","author":"Avasare","year":"2014","journal-title":"Clin Nephrol"},{"key":"R93-20250806","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2013-07-515957","article-title":"Unbiased RNAi screen for hepcidin regulators links hepcidin suppression to proliferative Ras\/RAF and nutrient-dependent mTOR signaling","volume":"123","author":"Mleczko-Sanecka","year":"2014","journal-title":"Blood"},{"key":"R94-20250806","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.2016.162917","article-title":"Imatinib and spironolactone suppress hepcidin expression","volume":"102","author":"Mleczko-Sanecka","year":"2017","journal-title":"Haematologica"},{"key":"R95-20250806","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1016\/j.bbrc.2018.08.102","article-title":"Fludrocortisone stimulates erythropoietin production in the intercalated cells of the collecting ducts","volume":"503","author":"Yasuoka","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"R96-20250806","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/fcp.12852","article-title":"Sodium-glucose cotransporter 2 inhibitors: a comprehensive review from cells to bedside","volume":"37","author":"Bagheri","year":"2022","journal-title":"Fundam Clin Pharmacol"},{"key":"R98-20250806","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"R99-20250806","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s40265-019-01146-5","article-title":"Sotagliflozin: first global approval","volume":"79","author":"Markham","year":"2019","journal-title":"Drugs"},{"key":"R101-20250806","first-page":"2117","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015"},{"key":"R102-20250806","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.jacc.2021.01.033","article-title":"Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial","volume":"77","author":"Packer","year":"2021","journal-title":"J Am College Cardiol"},{"key":"R103-20250806","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"The New England Journal of Medicine"},{"key":"R104-20250806","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/ejhf.2409","article-title":"Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced","volume":"24","author":"Ferreira","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"R105-20250806","doi-asserted-by":"crossref","first-page":"107729","DOI":"10.1016\/j.jdiacomp.2020.107729","article-title":"Correction of anemia by dapagliflozin in patients with type 2 diabetes","volume":"34","author":"Stef\u00e1nsson","year":"2020","journal-title":"J Diabetes Complications"},{"key":"R106-20250806","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"},{"key":"R107-20250806","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jchf.2019.08.004","article-title":"Mediators of the effects of canagliflozin on heart failure in patients with type 2 diabetes","volume":"8","author":"Li","year":"2020","journal-title":"JACC Heart Fail"},{"key":"R108-20250806","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2213-8587(20)30300-4","article-title":"Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial","volume":"8","author":"Oshima","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R109-20250806","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2337\/dc17-1096","article-title":"How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial","volume":"41","author":"Inzucchi","year":"2018","journal-title":"Diabetes Care"},{"key":"R110-20250806","doi-asserted-by":"crossref","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective effects of sirtuin-1 and its downstream effectors: potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ Heart Fail"},{"key":"R111-20250806","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/jcm8060779","article-title":"Effects of dapagliflozin on volume status when added to renin-angiotensin system inhibitors","volume":"8","author":"Eickhoff","year":"2019","journal-title":"J Clin Med"},{"key":"R112-20250806","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1632","article-title":"Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia","volume":"9","author":"Mayer","year":"2017","journal-title":"Sci Transl Med"},{"key":"R113-20250806","doi-asserted-by":"crossref","first-page":"e54442","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells--renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS One"},{"key":"R114-20250806","doi-asserted-by":"crossref","first-page":"e100777","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS One"},{"key":"R115-20250806","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000507272","article-title":"Competing effects of renin angiotensin system blockade and sodium-glucose cotransporter-2 inhibitors on erythropoietin secretion in diabetes","volume":"51","author":"Marathias","year":"2020","journal-title":"Am J Nephrol"},{"key":"R116-20250806","doi-asserted-by":"crossref","first-page":"109080","DOI":"10.1016\/j.intimp.2022.109080","article-title":"The impact of SGLT2 inhibitors on inflammation: a systematic review and meta-analysis of studies in rodents","volume":"111","author":"Theofilis","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"R117-20250806","doi-asserted-by":"crossref","first-page":"e1056","DOI":"10.1210\/clinem\/dgaa057","article-title":"Dapagliflozin suppresses hepcidin and increases erythropoiesis","volume":"105","author":"Ghanim","year":"2020","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000001773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:29:57Z","timestamp":1786040997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000001773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,29]]},"references-count":113,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000001773","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,29]]},"assertion":[{"value":"2023-11-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}